隐匿型脂质体阿霉素治疗乳腺癌的临床研究

The clinical study of stealth liposomes doxorubicin in treatment of breast cancer

阿霉素是细胞毒素类抗肿瘤药物 ,临床应用受到药物相关副作用的限制。羟甲基聚乙二醇 (PEG)脂质体包裹的阿霉素的结构是空间稳定性的 ,不易与血浆蛋白结合 ,因此称为隐匿型脂质体阿霉素 ,具有血液浓度高、血浆循环时间长、心脏毒性低、肿瘤靶向性的特征。PEG脂质体阿霉素更易于耐受 ,心脏毒性及其他副反应较传统阿霉素少 ,但在生存时间 ,有效率方面 ,与传统阿霉素无明显差异。与其他药物联合应用是否能增加有效率 ,延长生存时间 ,还需要进一步证实。

Doxorubicin is a cytotoxic antibiotic.The clinical use is limited by adverse events associated with the drug.Polyethylene glycol(PEG)doxorubicin which is encapsulated in PEG-coated liposomes are thought to'sterically stabilise'liposomes by reducing the attachment of plasma protein and lipoproteins,so it is called'stealth'liposomes doxorubicin.PEG-liposomal doxorubicin has a different pharmacolzinetic profile from that of standard doxorubicin,including higher concentrations,a longer circulation time,lower cardiotoxicity and enhancing localisation to the tumor tissue.The adverse effects of PEG-liposomal doxorubicin are well-tolerated.The risk of cardiotoxicity and other advers effects are lower.There is no significant difference in surrival time and response rates between PEG-liposomal doxorubicin and standard doxorubicin.If NPEG-liposomal doxorubicin increase the response rates and the surrival time when combined with other agents,further data are needed to confirm.